News

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed ...
Health and Me on MSN13h
Antibody Vs Diagnostic: How To Know If You’re Taking The Right COVID-19 Test?
COVID-19 testing includes molecular (PCR), antigen (rapid), and antibody (serology) tests, each serving different ...
The Manila Times13h
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in ...